Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Abstract Big Data Bayesian Truths to Be Covered in Oral Presentation at the 24th ECCMID Annual Meeting

DoseMe, a leading provider of model-informed precision dosing (MIPD), today announced Dr. Marc Scheetz, will present, Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy, at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) on April 30.

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.

Who: Dr. Marc Scheetz, Professor and Director of Pharmacometrics Center of Excellence, Midwestern University. Abstract co-authored Dr. Sharmeen Roy, PharmD, BCPS, Chief Strategy and Science Officer and Paul Sabourenkov, Lead Bioinformatician at DoseMe.

What: Abstract 05305, Big Data Bayesian Truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy.
Session type: 2-hour oral session
Session title: Therapeutic Expedition: mining old and new drugs for dosing strategies.

Where: Barcelona, Spain Fira Gran Via (North Access) Hall H

When: April 30 at 8:30 AM

Details: Title: Big data Bayesian truths: no vancomycin trough concentration target is sufficiently precise for safety or efficacy. The oral abstract will present background, methods, results, and conclusions around internationally represented, real-world, patient data with highly precise estimates of vancomycin AUC exposures and measured trough concentration results.

"Therapeutic drug monitoring is the standard of care for vancomycin because of the well-defined relationship between kidney injury and exposure (i.e. Area Under the Concentration Curve, AUC). Despite guideline-recommended target AUCs, surveys show that few practitioners calculate AUCs because of the perceived adequacy of trough concentrations," states Scheetz. "It is very important to note, however, that the percentage of real-world patients with goal vancomycin trough concentrations that achieve target vancomycin AUC is not clear. It's time to implement model-informed precision dosing."

Additional Resources

Connect with DoseMe on LinkedIn
Follow DoseMe on Twitter
Bookmark the DoseMe Blog
Visit the DoseMe Newsroom
Contact DoseMe

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories